Use of Insulin and Weight Gain: Optimizing Diabetes Nutrition Therapy

Journal of the American Dietetic Association

Volumn 107, Issue 8, 2007, Pages 1386-1393

  Daly, Anne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; CALORIC INTAKE; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; ENERGY METABOLISM; EXERCISE; FEMALE; HUMAN; LIFESTYLE; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; OBESITY; PHYSIOLOGY; QUALITY OF LIFE; WEIGHT GAIN;

COMBINED MODALITY THERAPY; DIABETES MELLITUS; ENERGY INTAKE; ENERGY METABOLISM; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE; MALE; NUTRITION THERAPY; OBESITY; QUALITY OF LIFE; WEIGHT GAIN;

EID: 34547134750     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2007.05.004     Document Type: Article

References (61)

1. National Diabetes Information Clearinghouse NDIC. National Diabetes Statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#7. Accessed April 18, 2006.
2. Saaddine J.B., Engelgau M.M., Beckles G.L., Gregg E.W., Thompson T.J., and Narayan K.M. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med 136 (2002) 565-574
3. Greisinger A.J., Balkrishnan R., Shenolikar R.A., Wehmanen O.A., Muhammad S., and Champion P.K. Diabetes care management participation in a primary care setting and subsequent hospitalization risk. Dis Manag 7 (2004) 325-332
4. Daly A. Diabesity: The deadly pentad disease. Diabetes Educ 20 (1994) 156-162
5. Astrup A., and Finer N. Redefining type 2 diabetes: 'Diabesity' or 'obesity dependent diabetes mellitus'?. Obes Rev 1 (2000) 57-59
6. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 24 (2001) 1711-1721
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
8. Nichols G.A., and Gomez-Caminero A. Weight change following the initiation of new anti-hyperglycaemic therapies. Diab Obes Metab 9 (2007) 92-102
9. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
10. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Orchard T.J., Raskin P., Zinman B., and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
11. Polonsky W.H., Anderson B.J., Lohrer P.A., Aponte J.E., Jacobson A.M., and Cole C.F. Insulin omission in women with IDDM. Diabetes Care 17 (1994) 1178-1185
12. Polonsky W.H., Fisher L., Guzman S., Villa-Caballero L., and Edelman S.V. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 28 (2005) 2543-2545
13. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
15. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., Taylor K.L., Trautmann M.E., Kim D.D., and Kendall D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
16. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., and Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA 280 (1998) 140-146
17. Lazar M.A. How obesity causes diabetes: Not a tall tale. Science 307 (2005) 373-375
18. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities. Am J Med 113 suppl 6A (2002) 3S-S11
19. Gerich J.E. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78 (2003) 447-456
20. Anderson R.J., Freedland K.E., Clouse R.E., and Lustman P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 (2001) 1069-1078
21. Lustman P.J., and Clouse R.E. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Compl 19 (2005) 113-122
22. Carlson M.G., and Campbell P.J. Intensive insulin therapy and weight gain in IDDM. Diabetes 42 (1993) 1700-1707
23. Makimattila S., Nikkila K., and Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 42 (1999) 406-412
24. Larger E., Rufat P., Dubois-Laforgue D., and Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care 24 (2001) 1849-1850
25. Kral T.V., and Rolls B.J. Energy density and portion size: Their independent and combined effects on energy intake. Physiol Behav 82 (2004) 131-138
26. Diliberti N., Bordi P.L., Conklin M.T., Roe L.S., and Rolls B.J. Increased portion size leads to increased energy intake in a restaurant meal. Obes Res 12 (2004) 562-568
27. Volker D.H., Leary C., and Gill T.P. Portion size of campus takeaway foods and serving size estimates of common foods. Asia Pac J Clin Nutr 12 suppl (2003) S25
28. Briefel R.R., and Johnson C.L. Secular trends in dietary intake in the United States. Annu Rev Nutr 24 (2004) 401-431
29. Dyson P. Nutrition and diabetes control: Advice for non-dietitians. Br J Comm Nurs 7 (2002) 414-419
30. Weyer C., Bogardus C., and Pratley R.E. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes. Diabetes 48 (1999) 1607-1614
31. Franssila-Kallunki A., and Groop L. Factors associated with basal metabolic rate in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 962-966
32. Lipkin E. New strategies for the treatment of type 2 diabetes. J Am Diet Assoc 99 (1999) 329-334
33. Hordern S.V., Wright J.E., Umpleby A.M., Shojaee-Moradie F., Amiss J., and Russell-Jones D.L. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 48 (2005) 420-426
34. Heise T., Nosek L., Ronn B.B., Endahl L., Heinemann L., Kapitza C., and Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
35. Guerci B., and Sauvanet J.P. Subcutaneous insulin: Pharmacokinetic variability and glycemic variability. Diabetes Metab 31 4 Pt 2 (2005) 4S7-4S24
36. Bailey C.J., Del Prato S., Eddy D., Zinman B., and Global Partnership for Effective Diabetes Management. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 59 (2005) 1309-1316
37. Chan J.L., and Abrahamson M.J. Pharmacological management of type 2 diabetes mellitus: Rationale for rational use of insulin. Mayo Clin Proc 78 (2003) 459-467
38. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R., and UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
39. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 suppl 3 (2002) S18-S24
40. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 32 suppl 1 (2006) 9S-18S
41. Korytkowski M., Bell D., Jacobsen C., Suwannasari R., and FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25 (2003) 2836-2848
42. Bohannon N.J., Ohannesian J.P., Burdan A.L., Holcombe J.H., and Zagar A. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 22 (2000) 1049-1067
43. Schwartz M.W., and Porte D.J. Diabetes, obesity, and the brain. Science 307 (2005) 375-379
44. Schwartz W.M. Staying slim with insulin in mind. Science 289 (2000) 2066-2067
45. Plum L., Schubert M., and Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 16 (2005) 59-65
46. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
47. Exubera package insert. Available at: http://www.pfizer.com/pfizer/download/uspi_exubera.pdf. Accessed June 19, 2007.
48. Ross T.A., Boucher J.L., and O'Connell B. American Dietetic Association Guide to Diabetes: Medical Nutrition Therapy and Education (2005), American Dietetic Association, Chicago, IL 90
49. Klein O., Lynge J., Endahl L., Damholt B., Nosek L., and Heise T. Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 55 suppl 1 (2006) A76 (abstract 325-OR)
50. Home P., and Kurtzhals P. Insulin detemir: From concept to clinical experience. Expert Opin Pharmacother 7 (2006) 325-343
51. Brunton S., Carmichael B., Funnell M., Lorber D., Rakel R., and Rubin R. Type 2 diabetes: The role of insulin. J Fam Pract 54 (2005) 445-452
52. Mooradian A.D., Bernbaum M., and Albert S.G. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med 145 (2006) 125-134
53. Saenz M. Insulin analogs: Tools for better blood glucose control. On the Cutting Edge (Diabetes Care and Education Newsletter) 12 (2006) 12-14
54. Hirsch I.B. Drug therapy: Insulin analogues. N Eng J Med 352 (2005) 174-183
55. Fritsche A., and Haring H. At last, a weight neutral insulin?. Int J Obes Relat Metab Disord 28 suppl 2 (2004) S41-S46
56. Heller S. Reducing hypoglycaemia with insulin analogues. Int J Obes 26 suppl 3 (2002) S31-S36
57. Markovic T.P., Campbell L.V., Balasubramanian S., Jenkins A.B., Fleury A.C., Simons L.A., and Chisholm D.J. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care 21 (1998) 695-700
58. Wylie-Rosett J., and Delahanty L. An integral role of the dietitian: Implications of the Diabetes Prevention Program. J Am Diet Assoc 102 (2002) 1065-1068
59. Jonnalagadda S.S. Effectiveness of medical nutrition therapy: Importance of documenting and monitoring nutrition outcomes. J Am Diet Assoc 104 (2004) 1788-1792
60. Lemon C.C., Lacey K., Lohse B., Hubacher D.O., Klawitter B., and Palta M. Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. J Am Diet Assoc 104 (2004) 1805-1815
61. Polonsky K.S., Given B.D., and Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81 (1988) 442-448